<SEC-DOCUMENT>0000200406-21-000014.txt : 20210412
<SEC-HEADER>0000200406-21-000014.hdr.sgml : 20210412
<ACCEPTANCE-DATETIME>20210409190210
ACCESSION NUMBER:		0000200406-21-000014
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20210412
DATE AS OF CHANGE:		20210409

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			JOHNSON & JOHNSON
		CENTRAL INDEX KEY:			0000200406
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				221024240
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			0103

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-03215
		FILM NUMBER:		21819047

	BUSINESS ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
		BUSINESS PHONE:		732-524-2455

	MAIL ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>a20210409supplementalproxy.htm
<DESCRIPTION>DEFA14A
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i6d0e444359be4aa9b5c8ffbb74e10be3_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;text-decoration:line-through">____________________________________________________________________________________________________________________________________________________________</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</font></div><div style="margin-top:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">___________________________</font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SCHEDULE 14A</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Proxy Statement Pursuant to Section&#160;14(a) of the</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities and Exchange Act of 1934</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filed by the Registrant&#160;&#160;</font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#254;</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filed by a party other than the Registrant&#160;&#160;</font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box&#58;</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Preliminary Proxy Statement</font></div><div><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Definitive Proxy Statement&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#254;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Definitive Additional Materials</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Soliciting Material under &#167; 240.14a-12</font></div><div style="text-align:center"><img alt="jnjlogoredtranspa031.gif" src="jnjlogoredtranspa031.gif" style="height:41px;margin-bottom:5pt;vertical-align:text-bottom;width:224px"></div><div style="margin-top:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Name of Registrant as Specified In Its Charter)</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">___________________________</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment of Filing Fee (Check the appropriate box)&#58;</font></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#254;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No fee required</font></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Title of each class of securities to which transaction applies&#58;</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________________________________________________________</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Aggregate number of securities to which transaction applies&#58;</font></div><div style="margin-bottom:3pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________________________________________________________</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined)&#58;</font></div><div style="margin-bottom:3pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________________________________________________________</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Proposed maximum aggregate value of transaction&#58;</font></div><div style="margin-bottom:3pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________________________________________________________</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Total fee paid&#58;</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________________________________________________________</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Fee paid previously with preliminary materials.</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Amount Previously Paid&#58;</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;______________________________________________________________________________________</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Form, Schedule or Registration Statement No.&#58;</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;______________________________________________________________________________________</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Filing Party&#58;</font></div><div style="margin-bottom:3pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________________________________________________________</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Date Filed&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________________________________________________________</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:line-through">_____________________________________________________________________________________________</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.5pt;text-align:center"><img alt="jnjlogoredtranspa031.gif" src="jnjlogoredtranspa031.gif" style="height:50px;margin-bottom:5pt;vertical-align:text-bottom;width:269px"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One Johnson &#38; Johnson Plaza</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New Brunswick, NJ 08933</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April 9, 2021</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dear Fellow Shareholder&#58; </font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I trust you have received your copy of Johnson &#38; Johnson&#8217;s 2021 Proxy Statement (the &#8220;Proxy Statement&#8221;), along with the proxy card or notice of Internet availability of proxy materials. </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As Chairman of the Compensation &#38; Benefits Committee (the &#8220;Committee&#8221;) of the Board of Directors of Johnson &#38; Johnson (the &#8220;Company&#8221;) I am writing to you today to ask for your support by voting in accordance with the recommendations of our Board on all proposals included in our Proxy Statement for our April 22, 2021 Annual Meeting of Shareholders. Specifically, I am asking for you to vote &#8220;FOR&#8221; our Advisory Vote to Approve Named Executive Officer Compensation (&#8220;Say on Pay&#8221;) (Item 2). I also encourage you to read our Compensation Discussion and Analysis beginning on page 48 of the Proxy Statement.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s executive compensation is intended to promote long-term, sustainable value creation and, thereby, align the Company&#8217;s executive compensation programs with the interests of shareholders. As evidenced by the changes we made in 2020, which incorporated shareholder input, we are committed to refining the program to further these goals based on feedback from our extensive and continuing shareholder engagements. These changes included&#58; </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; eliminating the three 1-year sales goals from our performance share units (PSUs), </font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; adding more structure to our annual incentive plan, </font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; capping the value of our executive car and driver benefit, and </font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; doubling our stock ownership guidelines for our senior executives. </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To assist you in evaluating our Say on Pay proposal, I would like to provide you with additional context and information concerning our treatment of litigation expenses in earnings per share (EPS) for our annual incentives and PSUs. The adjusted EPS we use in our incentive plans are based on the same measures used in the earnings guidance furnished to our shareholders and the investment community. While we acknowledge that litigation outcomes have an impact on our business and shareholders, we do not believe including extraordinary, non-recurring gains and expenses, such as certain litigation-related items, in the EPS goals and results creates an effective incentive-based compensation structure that is in the best interests of the Company or its shareholders. We do not exclude from our non-GAAP measures ordinary, recurring legal fees (including both internal and external counsel). </font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I have summarized below several additional points regarding our treatment of litigation outcomes in our performance targets and results for your consideration&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226; Excluding litigation outcomes from incentive targets and results is consistent with the Company&#8217;s past practices and well within benchmark practices among large public companies.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has treated litigation items consistently for many years in its reporting of adjusted EPS and in its incentive plans. We continue to believe this treatment is most appropriate and motivates the right behaviors. The Company's practices have not changed.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s approach is aligned with most large public companies which exclude non-recurring litigation expenses from their adjusted EPS disclosures and their incentive targets and results. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If litigation expenses had been included in our EPS targets for purposes of our incentive plans, the targets would have been lower. Therefore, it is inappropriate to compare our EPS results inclusive of litigation expenses to EPS targets that were set assuming litigation expenses were excluded.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226; Excluding litigation outcomes from our EPS measures&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">i. Facilitates the pursuit of appropriate legal strategies.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding litigation outcomes facilitates the pursuit of appropriate legal strategies. The legal strategies that are in the best interest of our shareholders vary depending on the facts and circumstances of each case. Excluding litigation outcomes from our EPS measures helps ensure that the incentives do not motivate legal approaches that are not in the best interests of our shareholders.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ii. Helps focus our incentives on underlying business performance. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our incentives motivate attainment of annual and long-term business objectives. Litigation outcomes are inherently unpredictable as to amount and timing. Including them in our EPS goals would create substantial goal-setting challenges and the annual incentive and PSU payouts would be misaligned with underlying business performance.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">iii. Aligns our incentives with performance during the performance period.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our annual incentives and PSUs are aligned with operational financial performance during 1- and 3-year performance periods. Litigation outcomes typically do not reflect the results of decisions made by or the performance of the current executive team. They often relate to events that occurred years or even decades before the performance periods, well before the current management team was in place.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226; Litigation outcomes are included in, or may impact, certain performance measures other than EPS in the executive compensation plan, so they can have an impact on compensation. </font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our annual incentive plan, litigation outcomes are included in free cash flow and excluded from 1-year EPS. The two measures &#8211; free cash flow and 1-year EPS &#8211; have the same weight in the plan.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our long-term incentive plan, litigation outcomes may affect stock price performance which impacts the 3-year relative total shareholder return measure and the underlying value of each PSU. Litigation outcomes are excluded from the 3-year EPS measure. The two measures &#8211; 3-year relative total shareholder return and 3-year EPS &#8211; have the same weight in the PSU plan. Litigation outcomes also affect the value of our stock options and restricted share units, which comprise 30% and 10% of our target long-term incentive grants, respectively.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226; The Board oversees, and management actively manages, litigation risk.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We understand the impact that litigation expenses have on our business and shareholders. We actively manage litigation risk and both the Board and management factor litigation risks and expenses into their overall review of the business. I refer you to pages 25-30 of our 2021 Proxy Statement for a fulsome description of the Company&#8217;s approach as well as the Board&#8217;s oversight of risk management.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226; The Company provides transparent disclosure regarding non-GAAP measures and material litigation. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly provides reconciliations of all non-GAAP financial performance metrics that have been adjusted to exclude certain litigation costs as part of regular financial reporting available in conjunction with our earnings releases.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s public filings include detailed information regarding material litigation in accordance with the internal disclosure policies and SEC requirements. </font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">http&#58;&#47;&#47;www.factsabouttalc.com&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> website provides scientifically substantiated information about the safety of talc.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.factsaboutourprescriptionopioids.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> website provides updated information on, among other things, the allegations made against the Company in recent litigation and the Company&#8217;s position.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226; We enhanced our shareholder outreach during the 2019 and 2020 fall engagement seasons. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the past two years, we have reached out to shareholders representing approximately half of our total ownership and approximately 60% of our institutional ownership. We have had a combined total of approximately 170 engagements with U.S. and international institutional shareholders during this same period, and I and our Lead Director have personally participated in many of these discussions. Based on the engagements with our institutional shareholders, we have not heard expressions of concern with the Company&#8217;s treatment of litigation-related items in our executive compensation program.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I hope this information is useful as you consider your voting decision. I urge you to vote &#8220;FOR&#8221; our Say on Pay proposal (Item 2). </font></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I appreciate your time and consideration on these matters and ask for your support of the Board&#8217;s recommendation. Our 2021 Proxy Statement, this supplemental proxy material and our 2020 Annual Report, are available at http&#58;&#47;&#47;www.investor.jnj.com&#47;gov&#47;annualmeetingmaterials.cfm.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Ronald A. Williams</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ronald A. Williams</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chairman, Johnson &#38; Johnson Compensation &#38; Benefits Committee</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>jnjlogoredtranspa031.gif
<TEXT>
begin 644 jnjlogoredtranspa031.gif
M1TE&.#EA9 3: /<  ,P  ,\-#=(='=4M+=@]/=M-3=]>7N)N;N5^?NB.CNR>
MGN^OK_*_O_7/S_G?W_SO[\# P
M                                         /B&&  T^1( "PSB=[W
MXG? 15T F(@8 )B(& "IM^-W> $4 '@!%       F(@8 $ &% "8B!@ Z!<\
M "#Y$@ D    C"KX=P  % !(#10 )         #X^!(   (     % "(EA@
M> $4 "\!   #QOQWR<3\=^#$_'<          +AS2 !((!< *" 7 $R5&
M    )  "                 (CY$@! DA@ !BKX=P  %  XDA@ G/D2 #B5
M&  &*OAW   4 #"5&  XE1@ > $4 '@!%  P^A( 51_X=T &% #_____0/H2
M !['_'?8!Q0 .)48 $R5&  XE1@  0        #X^1( 51_X=R@E^'?_____
M"/H2 #!6^'=45OAWD ']=SE6^'=((!< *" 7 $R5&   X/U_          !X
M 10 > $4 '@!% !X 10    4  <         3)48 #B5&  !     1\7 !
M_7>L^1( @/H2 (#Z$@!5'_AW*"7X=_____^0^A( J%E8?   %        0
M +[/X7<      0    #@_7], $\ ?@ Q #B5&       & $  %3Z$@ ,
ML/\2 & A7'QH'E=\__________]L3D, .)48    %  O 0  <)48 &B5& !H
M 10  +P*F"0   #:#%U: &/( 0    "(EA@ ;/H2 '@!% !HE1@ <)48 " !
M   !    W@4- -X%#0 T^Q( 51_X=Q@E^'?_____1/L2 -&15WP  !0 "  4
M !@!  "^S^%W                     /3"1 #5E1@ 1!(7 -F5&  A=$@
M_____W"5& !>PT0 U948 "'Y! $  !  +     !D!-H 0 C_ "$('$BPH,&#
M"!,J7,BPH<.'$"-*G$BQHL6+&#-JW,BQH\>/($.*'$FRI,F3*%.J7,FRI<N7
M,!$V8,# 0<R;.'/JW,FSI\^?,&DR> "TJ-&C2),J7>K0 0$ 4*-*+:" : .I
M4 4P3:D J]>O415L'4NVK-FS"1<$  L@P($& @MX18!6I%RV> ,0K<NWKU^E
M#P;@%9O0 =@%?S,*P L@P<&G7PDDGDRYLF6%#=:"U:L0P=< ER<R8 Q@+\'1
M8!F$7LVZ=4,'FMG297B5K6O:I $42 C9J^3;P(,+5YF <0";# VP-3#\H'+2
MJA&RC=Z\NG6EGDG#=2@8[W;K"W(#__A],+M7YM?3JU]?\,%BQN1QXXU?_2[I
MV0??>Z7.OK]_E >(AYQ#^K%%WW#FW7=0>%^A]]^#$%H6&UZ[/80:8_PU)QY4
M"-F'U7<1ABAB15V)%Q&#I!THW(8 X >!85^Y..*,-";5&V,'1'0C7AD*ER!I
M!?T8U8 U%FED01NJJ-"%N:7'(@*U>878D516B5-QXO6XT(YXY6B=D'A!$*!7
M IAFY9DSCIF;E@IQV:5(#R PX5>."138A@* B!&+4@U@9D,EYC8E1RB2=MQ%
M=^9V*$?/2<5F1P\HT)UX Q#4J*&$6?2 FN)Q9M&E\+F69$1,KBE2 VY*M2@$
M@>9VP)\6@2R96YT//> A7F5Z!.I\&+4:*D</D&F2 P?,R1BMF6TX )$4-3"I
M>%Y6E*QX@_^6Y"M>,C*4*EN92O3 M@:6!U:E!>T:E5:D@@M6MICQZ16M%)G+
MXJ,'<>HN /0"FN5$MMXKK$&R@E;0M5(Q*Q #!?KK%418*@P :^I*%5&P?%JD
MEKM:<EM0 PE+Q>Y""1@+)$3VNHNHR*/6BK)X2D(4,0#H2G2QPU"QFVJT=MXJ
ME9*R.OPQ0L_>^[-'#4,7$<8+R<LGN4G3[.\ I3(V](LB1_=R5%.+^U5T*V\-
M<F0'\YDO0E>#U2T$/;>E9=H2)^<T6\LN5+%",'KE)=L+]Q0U6#$W=#73#N&-
M5<L"34LSO#)U_398!I0<YD)@,CTW1.Y]1>[>X2X4-%13ECW>1'7_W^NIG9OO
M#"L$'3?($&R+QPCYDZ]_M9WGA']4-%Z -^0N7 1'%4"U EU=NT685_@0[ :Y
M:3Q!@F/=D*QG!S^O00]4;1#FTSG4NX/8N_J0TGF#E*I$DS/_&:S-1_61 PD4
MH#C,!2"0+_@ Y+Y0ZG1"U'OFX/M94/=8R5I%'(<OB*3O808)G:,.4KZ$5,XK
MHQL(  =W$(+9#P*T>TBJJ$._O.A)(2G[".8$:+X-L2MU#B)(!E<R0:A$CS<*
M\Q]#6A@5G'$$<\-#D@GM9+W.(,\@!$3<8Z;'JJ_T[2 TC,JC"K6SA52/10([
M7@@]8INCL6@@YJK= 1%(O!\6A%B* U\._PORLBBNSF$OU)J 0*(SJ(RMA"82
M")B.R, K'N2)$#S=:5A$'C=-;85D.\Q"]@<6&PZ21<#;B*Q(.) #S@:/6$GC
M0 #I$@)BQ6  XR-%W+6\B^ / (ED",WHZ,,="J1T!709S<8(@22ZT5*,VQ)8
MV@@6(2H$E6PA)45H"0!#ZHYF*8S=AA"2**SX$@*\C PFB?F^UOU*<T2,R.U,
ME1'LZ;*4"F,D!"87):Q<<$E.>Z/TI@A)K-!+@5,9IH7<94O0K6R9V%28.#&H
MR0J"!9X<(:0+!V(XL56DG/XB  (4()0%(*!LWW3(O8+YD"V228\.\5Q4&-H0
M5_+(;ZJ#XW(H\O])91V H#0QJ/LV]$&(^(NB#'$H8ZX)$0<HP  =I=D\'9+,
MMIC&DL^<B$JQ$@ #R$\H"8#IAMKYO'O-E"!..Z9#+*K$B4AT7!4%BYXB=M2P
MT2P \5N 4!1P %SZ)E;^JBH]G:G-D!03;N-4D$:<Y4PCEK0B4Z0(Q;R(D;)U
M<B(=_(HDZ>8P5CKDK&VM84=B.A6, )1/94T)F,0JD7[6LI4;PF=$]/DVE%(D
M?:&4)I]6E9%HRO5>,HS(3CG7$<<&-@!OI8@K&4L0RGIP)_)*X\ONBJ;:VO:V
M,3FL3>^X+]SZ]K<U2MT8J0K<XAKWN!?!W%XEV"3D.O>YMW%<!*.*+>@.6O>Z
MQQ6996'X..QZ][O(9"&@9!.2-HB"][SH[8_(:!M1MK WO?"-;TM0-MZ$8*^^
M\LVO?B?#Q*CX-7E@^>]^!TQ@B?3,(NLML((7[!>4)78@_24M@R=,85*Y%Z\9
MK;"&-UR4GE55M_CEL(@5S)B$#J1W#QZQBE<,D@A+A:BDNR>+9RQBUY(FM#3.
ML8Y14E-H[?C'*HY4 ?03 (&F%LA(3C))B'6C 1B@*DJ.LI2G3.4J6_G*6,ZR
MEK?,Y2Y[^7IE6ZYZ%!!3 YCWRVA629P(JSX1;<HX8D[_LXYGYCHU2N7,/L(0
M05S,13G[>2,/4!IJ$=*Q]S;G@7PK""V5^F<*T^_(<8GE>GHLVP W^M(/,6T3
M%X+.IJJGT^$SB&PPS6#=7M(A.$WQ9&R<6I2QEM17YK-_'](U2+OF92W#'$MA
M#=Z7:5-Q)KZ-*:]G:5Y?&M1>";&L:Y:>:6;O(+3,K+&QBVR>1J3'G[N.5P-H
M$'G9>MI8;IXVYZIGZ[CR("(+-KB?N^P%0H3-V;;.#U&X[C__S<+B4;5?#GAB
M&=<[O>F+LT:-QI*9O+HCJ]043;[]$8,S_"(.)PD>!;QDH>"9)4(Y>%.$TIQM
MM\VD>&K) Q9^D]%*N%DT"3&P_RPN<9:/I&$:]XA0'IZ2D:>\)$)1N4?2=U2)
MWA#>  !1-^]%<^FP:+L=NM>NUWDO0SNPF5YQ^D,(J7/(03U_2$5CK?(JM8EX
M_+&K41:^AVU8G'JS7 Y3=TJA6'36N4O?L#3J1)Q-S;IF3B,.P/9FS&3CS828
M8TZK.E/;;)*XKKV>3?GZ9A2"LD$;A.[V6\ !@*Y6ANB]Z^Y\VQM-[<_+NDO,
M=/<= O9B=JBDEI<OU&V1,560=F.%.XL[2ISFE*N'A%Y*.N*3P 6B@*O;+2T;
M/0@JS^;2RS=W=;ZOXMS?-L;;&_[=FSWSM^ 3'<Y'):'(QO% (/\^ C#+^ (<
M/-A.4H1ZJ)BQJ(CG9]=D&-F)R6EQ6%4 /.E*$&<?T9$JLQP9/;O_=^V1_TZ4
M?&RQ,HZ7$(HG;0CA %Q72.1C1PN2&@,W,CZ!:-WU2[E15LG7(VQ3)\XW:^G2
M.@-P -+&;PF1.C+20%^#=5;%,H5Q/BJ4?@W1@95E7D-7@4OU5%)1=/@72%Z1
M.Y3_9!+DEA?ZLSC:]W]Q!!+%)D7Y5A F2%[T1Q!NAQ6U-T0;PA][,UW,!8 &
M@4HE56T9IH2Y472J]!4-J$Z-9$1.Z( 747[N(@"#XH4P]G@^ID&+LUWI W?Q
MY#$&I(:0!4'SQX=R6&=(!(/F8ED_.(CCETDL4G0R"!44MU3K(EI>I%L_<X@H
MX85#TA!!>&,7UW_B(742@6Q']20$@X5V5GF% U7M585@DD,6U2,4F(.8(8!9
M03(LLG03@3)Q6$<; EA0@71RA((&,2T#\$%)Q&CMH7@>*!%Y!8IHPR? 2&R(
MY!$$]%\'-'WGH5" &$20B">QN$_: H,"X6):E$T@MR'(_S@1^V-@?(0Y;V2)
M!:$FZ7@1':14-2B!$J&,?=*)R8@KFQ10[(B.\C*/5+A08[<O\F**!$%+U-%,
M1[6 JB*& D$_52<0#A.-$<@8: >!#/%F@:4P!/!10[$0#6!0A)5:;.@\$W&/
MN;%[ W,L.J4P+FF1B.1JHN$P/:=)IH:,H!8SKM=GFDB+&#F,7?.()I>3Y(1*
MN/@1$/EV&)&2SL19_[@ASH@0HQ5S$C64TJ@PNYAUOS<0F^@5$ME:'SDKG06-
M%8&)0\43XP,2FM8ZAD6+3J.55MEY4^DN:C=#2.-Y"J.0!T%W1.)\C_B"99D7
M%1DD>QF3;^.7&+=W1HAY'T%FP,ETF'0X@&.9@(I3@!W!-D7X*:R7$7V'AQ:"
M@U(A #,Y$375F18!>$MH% JTE!NQ:!M)<!XQ>PXC  G CRO)&'3)$)2EFA@1
M4Z=)-^\3-X;%=<4(A A >0U"F4VA.,.9@KF1)SV1.HS90J+Y;]K)'B.T$.47
M<]L9GBY1.GZ%-^)YGD;"DBZY;=F)GNXI$J#6E5NI?^]9G_]!0+HY27@AG_;9
MGR6!/Q:Q+9?IGP3*%YC3FUF8B 6ZH"B!2OS)BZ'&H!(:&MAC$72'H!.VFJ%6
MI*"4(U4:^J&5L3^,Y6QY":(F"A'=HW*.,Y@GVJ(_T3-^I5O@Z:(TVG>=DI\T
MFJ-&09IL09 Z^J/: UHX"J1$>A0XV)Y%FJ1*NJ1,VJ1.^J10&J52.J546J56
M>EL/D !>%9W587,C>:5<U@#%,H!'$G%@>ER!1G01P@"^QYAG*F((XRXLRAI-
MB:%O>AW]LAF)M"M(ZA=1:$0$I31<>J?GQ9I?40!_$I9#NAK.5P ,("F+1ZC_
M(0(^DA1A57EKY480NBBI"V:H/0A1;32C?<&2YS*?K\>IZ^&+A74_8-$?,:5+
MJ3*GJ.I;;WER".%B?8H6$]1.HS:KS:%/.11ZHHH6,LA=7^6KYZ6J4H&  X$_
MYV<=A*54&H.LT46;K)J$VM:2QLIMU'I=WRB%#B%K@_H7I'JJ!T&JB]JM3-%"
M^%6NJ70=\)80I*JNT-5CK$0_ZD%#/R,K/DJO8Y%7S$J6&ID>>M<RJ#2L_LH>
MUE>+#\&>Z1&6'&FJUY>PDY%7)5I$.=4<2?0QJ3*@%/L@:@D ZVFMS5$V,J&*
M'\L7-O:@+22K?%$V["(RSYJR9W(UNHEM"#L6(<LA0 ;A8OU*LT5Q-0^Z3;GA
MLG5!5RXVKD"['CNK676GL8#81FZZM$@!;S_+=4:+%C^D6W9*M=Q)4AM*LGEF
MAA@KEE[_>Q8FVU* N"([1(EGBR8[6U9W>!TDV#O.^;8WL;&2"+;RMB$R>[=X
MFQYEDY] E[5F<4"E<ZF!ZQ,\EWMD!R<)@#^(PP"IXA: "Z&?YRW)]+,30S]*
MRSQ=\[GY(16<JQ$,T%4X\D5*8P Y*YFO9;H=10#I2A8A%[;'MV0&@#+ML9SC
M(KJ(Z2]3^! +\$F:*7,=E9QX!R[(VQ%,=+G>H@ C=5&MI92CYQ$*2!J(JDB0
M>1*-.X8L*'-?%UHV*A6B>R\!NS')=[Y_Q9P 0)E-V;[:^Q7.FT#OVQ;?L;-8
M@:%TMEDD@I>M\7S@Q"*^"[IFJ9]X.;MGN#3Y"94P0RB<E);)_Z>XUTI!($&Y
M!CD0#&Q^8UF_4%&ZIY2Y)M&]E<FWJTEY]I,V T  ,27!! &QD4@Y<OFN%=&(
MK7HB#@.:I'&W>=J7?T)(*;QMP5M!,7QV$.&N&5L9:QO  +RW:ZE#FT$ !* X
MKT:"$/&3'$H1^IB_$L&C76O =U<1<>HP=P4N4!Q34[/#3E-6&?QB)J&W>_B$
M#$'#%!R(/<B#$ 0H/-HBMI?&%I'%7@-[,F41-CI/:6H<!M!!IH@]I[,_ ])[
M-Z;")N,0'&RNE[& HVB7M4*::31\Y^I@J_-^"@,1?ARA!PF0W=A7%Z&,L D!
MGLHWD4L:QR0O*(5*Y%'(\/%4)+2P1?][$FG+=$EL$..K5PJQL +@4R UR30C
M0*FS++[W8.+WQTH<20S,6!R<1FR52QF25\C843U%4'9BQ5)A9D9'MLST&<,K
MC#D1,GG!CW$;$4TYCV@L.L)D( ?P4VQ:F .[$)B3 ..[2XN30^;"S.+X5[2H
MD(UJ)KH,O\"'*_*#' WPOK]3EX]K3PTBQ_%6$A,M2W"LK%C#AOR)S%3)'W"\
M@JIB&CLXPB7MQ4\+1%\1+:\H$>SK%6+!T;TDK^*!D;;\-@6 7^A,TN2;P.2L
M$XW(2#1,<TR5$/HD /=\NR09TYN%  -"Q4F7C0/1TR?;T@FZRT\G.RJ=(A+Q
MS+Y#%(Z\&8__PG7B5*ON$@ D=-+.X8)II=5 N"'JZ].&<AI=XR+I@R@,@  %
M<#5E!<<!K8BMJ9=?^-9B*Q"I SPO?<IG%\R'BF=)Y+&/B@"47=F4C:W:&-2\
MYV] ?80_T6-$W2G7AEAQMQD@ F]PYU('0 "*Q\1,#98B$SU6K6@12]>\@HA2
M^"?PB!#RXAAY'!8-4; 7X0![;=F534M#R]:$.<==?<0DH7@N:7RZ\;JB]KU(
M>,5R,]&E<TS*79 ?8L<K#6J8M-A-HX("@;_ +<J:O1%M>8Z>'8P/=8KX^)1O
M(P#56Q#;]G>B[=XL@Q<H-;<@(2MS_8Q!C3EO-=NLC-E9[=6_R]S+%PW7PRRS
M?^)0QLG8SFVZ+]Q0]->$WLW@_REAQ+_(WT*JSUJH$0J>W8.M6WO5W1 V2QK=
M6WW(4Q!%W@?QIV'=@M,HXH,1$JA4AIZ=17DXW_Z,S\D)/F7%=0]G<N"H$)=G
MN W.K8&CAJ5H7E:]0='LX<B$U=N*Y?+=P4$NA&_\WC>4X5$^;"K>)@/=QN+!
M<!8-%<")N:2!P+Q-YA9X@2_"V6DXV&!IG?7E.:HQ1X1=A0A!0%-3OP_JY[9S
MXB@>1T ^SZ\=D';.$/N[Q&C.Y96N>V&>&UV<$&RAFR38BG7^Z#A$7=^;.KL(
MCZJ'3PGM%?SH2JNLWM!<YDMHXZ_TXA"^$M^:;!B5T8>W(9O.A"@+AOXRM?"M
MY_SJO?\@:>$DJVOFI>3S9%%.SDL345FR+N8$85K0AHZ4HXSQ0=Q\/<J%?=6"
M#M-\,K\0P&<SJ>0UG=F>G>L/!];I'8Z&1TM#D^O6'=R8OA'(UIOJ+L.7?NNS
M*5@-)RB<=HL4T>92V5C^/>TQY-H*PI)!O.LGA:*=1^NVVN' /=15+'>:\DFO
M7M47F>F/CMRS>"\A:<\91Q,)@ #@'E@1_^2H"'UHN8;> >GW,I-S0^A?'<@H
M[>%T]_+\Y)BM#1'273\(3$BEZ^S(;NF:1NPGLU*P4K^'N>H0Q$AX\_$@+Z>*
MR?-.-?&E;"@7=DA?42WEAZ,M_RK:\SZLI3#\SB>.D=,\)7C_1=]7\H?#J?M%
M CB8CNWFXN04,:_A'&^[P+NHSUQ5$O5)8^,F1Y0;$@SBFR%P'NF/?'DO5><Y
MG!'&A[H29E<FR/QJ]H[/ @]7,[_U]^+!#W[3JN4T;^Z5Y@3S7Y&NOSU*"'S!
M,N-,+"Q7*5\3&%_KP!)3KS+$%P'.'SF@#K7V#B/9@>^X#B.?H.[$P0<ZH/_W
M#@_CRJ]Y,:&/-"R:G]]6Q2OZ]T[Z8J<1GM/%"@/T"4%+LAOC;.&\L7]T&S'Z
M0^XP3J\28/+K)2\> I"2&K'W3R/G  $! 0""!0T>!*  PD*&#1T^7#@ X42$
M"2!>Q+B0 46.##)^%,A1)$$$(!TZ_^!H\8&!D01,FFP08.1,F@85OOPXL"9!
MCS@?HMS)\8!/HD4;/I!(\69(FB6-9M09=&8 BT\S%FAJU:&"G0$>:(6XH*93
ML! $!#6@]8%,J0.^EKVH@*W4E@[@/HPZDFS9I%+3W@7\, '" H%!QJ3HE>'<
MD3T!.^A+E^. !H8A )U9&2Z!G7\#8Z6I&2S7KJ*-#J;KV?(#T)(Y!M@;^.Q4
MNW W2EYJN6Q>@X4?CM4-D0$" HP/$CB@H';PBPEF$Q2 X*UN!9$!#,C-7,%S
M@@4<6V9@@'$  ]\#*VA=D$""Y<P_-D!0@/O! 042F'9_%,%X ^UU.TB LX/(
M,R^_NQA@*W\[ ^<KJ$"Q:"KP/P4,$' B 0A (,+\'!#/( (68(Y#_O#[K\."
MHIO.LNH.BLZ_NQQ 8#X!# #1P(P>6." XA)#3CD;'6H@O>L22%&W\!@<  $7
M?_2IPH.67(@WBF)CLDHKK\0R2RVWY+)++[\T";/C,K*.(@W!1#---==DLTTW
M_]MD\#J3LGJS3COOQ#-//??T\K:*0")M)#X');100P]%-*,X77KI@,P2A312
M22>EM%*,_#Q(08QF8M123S\%-51+A82.*$PGZE1455=EM557PYR2*"<G.O-5
M6V_%-5>B CV(1)!.1<A778<EMEACLYR5H &,2M;#8Y^%-EI/XUS6*& -HE):
M;;?EEML'$=+4I&8+ZK9<<\_UL@&*AGI*RH)40S=>>>>EE*6)H)RS(WKWY;=?
MGWC%5BN.?/.W8(,/]K),@O %"35:$88XXG,!5D\K>Q&"5V*--^:X*(4!J/$I
MCH3MN&230;V6()(;5NIDEU\NV5%4M5(X )AOQCG2<153)<IA@VS..6BAY4TY
M(:OBS'AHI9>L1E/,@]CU>*)PF::ZZE?=Y<DH=1%2S&JOOZZR:)Y-<C=IL,]&
M6U)2"YH:HSAK33MNN7%Z0*1J35+8[+GWYKM.K EJNZ&4X>Z[\,+'-2AI!]8F
M*&3#'X>\Z:DB7,"X$XN,//.^+7<- *@U!SUT*RGN/("514?=Z[]I,CUUUU]W
M+\[.8*==[HM'&H#PVG?G_:4&9,<8\]Z')[YXXX]'/GGEEV>^>>>?ASYZZ:>G
MON5ZZZ_'/GOMM^>^>^^_!S]\\<<GOWQ#'9C0.@*$-[]]C>';T2;WYZ>T@=LY
MRE;;!4P\T8#3Z?_>BF:"K@<$""$#(!( (]< Q)FI6PYHH$$$\#\%5F\[01%
MN2I7$[U5T&L)X)P$.<<MTG'*@]ICS4R0MJV52,9Q)ZR:7 ;6GF\5A&#0*AI-
M,@C#Z:4P,=)I"*ET=ZO[225_/+Q9 SX&@ )@KFX(&>*KE@B KD& <3=$XO)\
M]B?!(&2'T-H:1SSC-(.\,(LOVV*FW.;%:(61(F/3UQF1AY3)0*F&!3EBKF06
M1X9@[6YR_S19"SG2MK7E\59W/"!$QF5(0*8.,11Q"T;(2!#VY2J""BH:!1O)
M+SH*)2<489BM2FB0)>ULD[Q[Y$1:IZB9/2N"8UL(1\QX2H,U4 "57 @B"0++
M7.60(&8S)2U?E\J),))Q@7L5XPRB(?P)$V%%/$A5;M1,8TTR6!<)IC-#]P#@
M43&4$$AC07!Y-1->A)K:Y)<O _!-""Q1DZOJIK(PDDUT1@Z:O8$)1WAY*S>F
M9%,.K">]IB@GD^R1:\=:'1[G&:N /JZ?$Y'F1T(( $:V*IX+^^?#&HHN7P)@
MGT 2"19S94TH+E1J&RV<,AOTDGMFK5@)E>=%BH;2<ZGTESCI9F!%5]72@V2$
M(^RDZ=+6,I,AZM(@QZJ)2/OXQJ!RBYLSZ:!##*K183U1A9>"9%/C9M2#1'&B
M'C463$EB4BYJ%5H.^.HN<4)2<KVT)ON\9T3-:C6Q(G.I(OFHJ]*Z4G-29*[_
M9]6A3WA*$&-=]*80L2I"_OJUP8[U)8EEZ+ ZRM<N3N1SB]750T&)$\V.B5B=
M+>9%L*93S)ZLL4STR51#2RRQNO0A(1QG:57%5H/(]2.-S2NK6DM1Q%+DB[(=
M6FMCVQ (%2N"1X5(.'D+W%SME:"/I4EN=[J3;-USELQ]V2C5B!.Q1C%40>DK
M&[%[*YL6Y)U,:8EQJ?N0SEYVO"^C;4'^:!+#>O=3DVVK0^YYWO=&2KF$(<I
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MHJ08R)7J7)*MQ@ "-'&QF]:S3X)BZ4^E6)5@=IF.%)V\3,LJ**#630,.$)D
M1 A'"" .LD_]DE2O4VL&F(]W;.2 80^H/ZM)@'7(D^.BY(7;_\E1_.3WD <,
M)SX'0, "</V4_2$I@89!#V%Z3"GP$D4J5VJW01"\D 8D  $&,  "?!0<6Q]$
MJ2:)MP2!:* %%, X A T6.PGHXC#Y3FT#G8"*,2U):$/ 0<H  +NDY\".GQ
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M;&H,K>&(%K-O?K_2=@W:Y6OHLPS&2>A.SD#.H3%=[NKM"HS)*K+X<^W1#F;
M&*6]AN!4@T/![:Q1=&FS_\-,;S;>XWU4((PB7W['TIL,H]A%H.I?(+&<?<LS
M-Q-G?;I:^;!2W?EAGT#3WUYD-"YL6L2U]:PZ-V/AYP()EC6J"NW>T/,)D5SL
M]M9M8.Z<.\/C<)I/NA&P! 5KU-Z)0&[B@])LH/;KAR8]@G6-',M1HQIH"$@9
MK[A!-W/07SSL7YYF001PI@V_FF&?YQX8T(0) _9/U6.\ O]:J5!NK0 >XJ9M
M95VW5)SK)XWGQ-ULCY;"JU@7[Q11J6!JJU"F_KZQ'Q?8U :ICPZ.R:OQRC)L
MD+!J/[8*%8?N$?=F_S[;?&:65.,V[OR8@V;%L2QPMV1<G)@B'"_N"H]P36:(
M>_]R5=.#8B <  +@\P+@<W$+Z8<8PBZ$51EO".UB<I%6T0<7E)2I\F$.< HO
M)XPLRY." /?;%9W3BC=MOOQ6L^4N)X:@TSJ-.0$S-DNT"I:F#_[JTT$2&==X
M,$^_G*=(VF]SO98"-@Q,%28;2EID\/ F;<GMG&^SM>D8)==FQCSWK6^=.GY+
M*S/$[&LUBJG<03;+\ :'9D:7##COW 37X<$&=@!X=(=0KJ5 ,HP#S/4A"D'M
M/J/([QV,UG#O<@-YT\ZK7EB/S<Z!N$HJ(,/*: \MQ"($0F[_=JEPNOF&CMB"
M)B*&J43/RF93DI5>9O$E<<^&OK-]"@!)T8(%#-XSCV>3?%P7WR50LQ_6:;OD
M?,62?&+)0,2D?9K0)HC+VBO_<WD":)O/HXE_3U2T&'/DZZ8DMY')JPQY]\M\
M5_8OM(J*%WCFU@HK;#Z$A_.-WGE+!\:C'PF"C_.@Z/3F;$/!\3<^EU+DT%HA
MK^[K&RA&B?8:O$:KMQNM*+BSU'.RKL97='GS,@FC2F,5M(JZW\5F;W*)_NJ%
M_W1XP!BL/FX<.6;[,KQD@S=ZNAAW2:<)86;A-L]Z[(P@A<T[D9]$X5-Z'R=(
ML@X.)+:,>C?\6%/RQ'=D=Y>*QUW$LI#&LT13X33J4@GKHF\7U)=?MZ<+V%](
MS ^,_^UHOL!]RC]=2%YZJ<!ZL@KNI[A. PU6BIWZ8"\*X'<-WS?;R-<*S;<A
M-C$Q$'X/[1<)N&A^<9SMK<8=L.@<OU=H*%=]IF_N'EZ(>!*^YAU2]=_<(,]&
M<63P4E]HW04(" ('$BQ(L$$   H7,FSH\"%$  $:&*QHT6#$APPN<B3((&-$
MBAU'#B0 LJ$#DAP%G'PX427!!!D'G$0 <^0#FBUW9O\T<',D3X4I?Q94$!3B
M1J)*E2)X:',I3(0[&RS@"=6@T:-:%0YX<)5@TYT"OD(HH)4 V8$?>:*]NO:L
M4I80!23,&&!H6JE;CP90D%9@UIUMK^K<"Z#KW\00<MH5:;;ET[^,#8,DX%5Q
MW9-XKSX6K!A"V):;EP;FF0"J@;V(/T-(3=GN M8F=XY>&EJK3]:*;RL,H-NB
M7H@%!O),^G=!YM</3RM^6SFM@Z-^,7LFVWGG2Z4/D@>-K+B!7.4/+7^.7IUL
M>*W&?W^]SG#XP-(9O2=N4%BY@<NLY3]<G78V2-E]QEU_B?$7T0%D5144>>Q!
MX(![E D0VV_F/5<?@2#EYF#_6LXI1"&' SF0(0#K 0C2>HDA0*)6?;%W(D3,
MY;73 +H=Z-!T_V$GTE6N\90C>PND]YH!M25V0$M DL5;DB%^->1"( KTP$[T
ML<:  2Q"-$ "^CDXF4,"\%C??0T-,"9K/CI4@)=_(1D1 6A^99^&1G+8P %:
MNF2 G+^!Z5""NCV@)D0$I.CD5>E)&:*'"PG0)I-(?9E F2<%8,"B["E XH:*
MW:A0H+\%UY"+G]$9D95?K9B1 $HBJD"$)W%IYWX1!9#I7PQ4"FB;B-XTHDN]
M0@ C1*F&Z  #R3+0IZ\$/9 LK5<FV^R4R3*K6P/0(IHM ]%26]"SRA[ZK8C:
M4HMLE++"DKO4L^JR%RD H7JTT[B,BNLNM=SBJQBZU[+'K;?-3>MDN/6N6Q"W
MYA[L4;K?BKLP48TJ-)A!\#9D+,09:[PQQQU[_#'((:<)$:X"T2LRRBFKO#++
M+;L<<;$<2>P0QB_;?#/..>N\\\W$"L61SPX9S#/111M]--('W^@JN) E_334
M44L]-<X^!["OQ0Q1O37777OUO?.-0P\$I4,R?GTVVFFKG;;/8XTT<T-KRSTW
MW763)BE)03,DMMU]^_TWX"\^Y#9))U$<..*)*TYTV#!EK=#BD4L^^>1MWW02
M?)1KOCGG#D/$]$4RS=0YZ:6;GC2A"A&NDMX*U7PZ[+'+_F",/\$-ZNRYZ[[[
MP?#N:U#K)?(^//&29]BI2K<+7SSSS3L/TXW^6M2Z;\];?[W7EL.<$?;=>S^\
MA0V9#5/K\GY_/OHVO^E0P!7=CGSZ\<N?.-F9_]0ZW_/KO[^O#=2NU(+PQK\!
M$O!LJ5/([Z87D=45L($.9 W9&'@3B]7H@1:\(-$"*#ZHL&A\&/SF( @YLKZ&
ME"QO$?%@"%.HPHUE2(*7B\@*8ZC"\#'D<#\AFT1DJ,,=4FN$# $=2>#V.AX2
M$7VQ D )1^*__Q6QB4[\"I5<<A6+/;&*Z5NB0ZIGF[E8L8M>[(@/%S)$CNP*
M "C\(AIW=\!X$89D:7SC%T,"E9FY$(YV/%U$\F>1F=GOCG[4H>C"U",W_K&0
MI/L49R"20$,R<H!!@Q],HN@02#:RDH$[8@65@L6& -&2GM0?JJ 2QAQ^LI2
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0V,4RMK&.?2QD(RO9@   .P$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
